Welcome to our dedicated page for Biomea Fusion SEC filings (Ticker: BMEA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can read like lab notebooks—hundreds of pages of trial protocols, R&D expenses, and dilution clauses. Biomea Fusion (BMEA) adds another layer with its covalent menin-inhibitor pipeline and beta-cell regeneration data. If you’re hunting for the exact moment a dose-escalation update hits EDGAR or need to track when executives sell shares ahead of data read-outs, this page solves the problem.
Stock Titan’s AI reviews every disclosure the second it posts, turning raw text into plain-English notes. The platform flags:
- Form 4 alerts—search “Biomea Fusion insider trading Form 4 transactions” and receive real-time signals
- 10-Q cash-runway and expense trends inside each “Biomea Fusion quarterly earnings report 10-Q filing”
- 8-K material events explained for clinical holds, financing moves, or trial milestones
- Proxy statements outlining “Biomea Fusion executive compensation” and option grants
Each document links to an AI-powered summary that answers common questions—“What new risk factors appear in the annual report?” “How much did R&D grow this quarter?”—so anyone searching “Biomea Fusion SEC filings explained simply” gets an immediate answer. Additional long-tail queries like “Biomea Fusion Form 4 insider transactions real-time”, “Biomea Fusion annual report 10-K simplified”, and “understanding Biomea Fusion SEC documents with AI” are already indexed.
Whether you need to monitor Biomea Fusion executive stock transactions Form 4, compare pipeline spending across quarters, or decode a sudden shelf registration, Stock Titan keeps every filing organized, summarized, and updated in real time. No more combing through PDFs—just clear context for BMEA’s science-driven business model and your next investment decision.
Blue Owl Capital Holdings LP reports beneficial ownership of 3,800,000 shares of Biomea Fusion common stock, representing 6.13% of the outstanding class. The position is composed of 1,300,000 directly held shares and 2,500,000 shares issuable upon exercise of warrants. The filing states the percentage was calculated using the issuer's reported outstanding share count plus the warrants. The reporting person discloses shared voting and shared dispositive power over the reported shares and confirms the securities are held in the ordinary course of business and not to influence control.
CVI Investments and Heights Capital Management have reported a significant stake in Biomea Fusion, collectively holding 5,834,871 shares representing 9.9% of the company's common stock. The position consists of 4,450,000 direct shares and additional shares issuable through pre-funded warrants and other warrants.
Key details of the filing include:
- Heights Capital Management serves as the investment manager to CVI Investments and can exercise voting and dispositive power over the shares
- The warrants contain a 9.99% beneficial ownership limitation clause
- CVI Investments is based in the Cayman Islands, while Heights Capital Management is incorporated in Delaware
- Both entities have shared voting and dispositive power over all reported shares, with no sole voting or dispositive power
The filing certifies that the securities were not acquired to influence control of Biomea Fusion or in connection with any transaction having such purpose. The stake was reported following a recent offering referenced in the company's June 18, 2025 Prospectus Supplement.
Biomea Fusion, Inc. (Nasdaq: BMEA) filed an 8-K disclosing that on June 17, 2025 it executed an Amended and Restated Underwriting Agreement with Jefferies LLC to conduct an underwritten equity offering. The transaction consists of (i) 19,450,000 newly issued common shares, (ii) 550,000 pre-funded warrants (exercise price $0.0001) issued in lieu of common shares to certain investors, and (iii) 20,000,000 accompanying common-stock warrants. The company also granted the underwriters a 30-day option to purchase up to an additional 3,000,000 common shares and/or warrants.
Pricing & Structure: Each common share plus warrant unit was priced at $2.00; each pre-funded warrant plus warrant unit at $1.9999, reflecting the $0.0001 exercise price embedded in the pre-funded warrant. The accompanying common-stock warrants carry an initial exercise price of $2.50 per share, are immediately exercisable, and expire 18 months after issuance. Both warrant classes include standard ownership caps (4.5%–14.99%) and “fundamental transaction” protections that allow holders to receive equivalent consideration or Black-Scholes cash value upon a change-of-control event.
Proceeds: Management estimates net proceeds of approximately $37.1 million after underwriting discounts, commissions and expenses. If the 3.0 million overallotment option is fully exercised, net proceeds would rise to approximately $42.7 million. Securities were issued off the company’s effective Form S-3 shelf (File No. 333-267884) and are covered by prospectus supplements dated June 17, 2025.
Key Takeaways for Investors:
- The raise increases liquidity by up to $42.7 million but introduces immediate dilution via 19.45 million new shares and potential dilution from up to 20 million warrant shares plus a 3 million share allotment option.
- Warrant terms—low $2.50 strike and 18-month tenor—suggest near-term overhang yet may facilitate rapid capital inflow if the stock trades above the strike.
- Standard indemnification, covenants and limitation of warrant exercises above preset beneficial-ownership thresholds are included.
FAQ
What is the current stock price of Biomea Fusion (BMEA)?
What is the market cap of Biomea Fusion (BMEA)?
